A drug that targets epigenetic proteins, aimed at boosting so-called “good” cholesterol levels, showed positive signs in Phase II clinical trial, its maker Resverlogix Corporation announced yesterday (August 28).
The therapy is intended to improve upon statins, which reduce the levels of “bad” cholesterol, or low density lipoprotein (LDL), but do not increase the levels of the beneficial high density lipoprotein (HDL). Trial results showed that the drug RVX-208 from Resverlogix was able to increase HDL levels in treated patients.
The therapy is intended to improve upon statins, which reduce the levels of “bad” cholesterol, or low density lipoprotein (LDL), but do not increase the levels of the beneficial high density lipoprotein (HDL). Trial results showed that the drug RVX-208 from Resverlogix was able to increase HDL levels in treated patients.
No comments:
Post a Comment